How to Profit from the Cure for Heart Disease

A breakthrough discovery shows how CRISPR technology could ultimately cure heart disease, and investors are salivating. You are receiving this email because you subscribed to Energy and Capital. [Click here]( to manage your e-mail preferences. [Energy and Capital logo] How to Profit from the Cure for Heart Disease [Jeff Siegel Photo] By [Jeff Siegel]( Written Jul. 05, 2018 Jacob Sanders was a beast. He wrestled in high school, played football in college, and ultimately competed in a number of Iron Man competitions. At 28, he became a personal trainer who worked with professional athletes and amateur fighters. His diet was comprised primarily of organic meats and vegetables. He considered processed foods and sugar the enemies of optimal health, and in all the years I knew him, I never once saw him drink alcohol, smoke a cigarette, or take any kind of performance-enhancement drug. Sanders was the very definition of health and wellness. So when he died a few weeks ago at the age of 44, I was shocked. Last month, Jacob Sanders was found unresponsive in his summer cabin near Lake Champlain. Cause of death: myocardial infarction. A heart attack. The perfect model of health and wellness died of a heart attack. I was blown away. How could this man, who lived such a healthy lifestyle, have a heart attack? A few days after his death, we discovered the reason. A Cure for Everything? Scientists at UC Berkeley are calling it “the Cure for Everything.” It will allow doctors to delete cancer, heart disease, Alzheimer’s, and diabetes. And MIT predicts that it will disrupt every corner of the $6.5 trillion health industry. We’re about to see three tiny stocks becoming the next Bayer, Pfizer, or Merck! [Watch this video to get in on the ground floor.]( A Lucrative Lesson in Genetics Jacob Sanders was born with a genetic mutation that made it difficult for his body to regulate fats in his blood. But because he lived such a healthy lifestyle, he had no idea. He didn’t experience the typical warning signs of heart disease because of his dedication to fitness and nutrition. In fact, the doctors told me that had Jacob not been so dedicated to his healthy lifestyle, he would’ve died years ago. Apparently, most folks with this genetic mutation — at least those who live sedentary lifestyles — don’t make it to 30. Still, no matter how much one focuses on health and wellness, the death of Jacob Sanders speaks volumes about how our genetic makeup ultimately determines our quality of life and life expectancy. And this, dear reader, is why I’m so incredibly bullish on the gene editing technology known as CRISPR. Not only from a health and wellness point of view, but from an investment point of view, too. Investing in the End of Disease If you’re a regular reader of these pages, CRISPR is not new to you, as I’ve been writing about this groundbreaking technology for a couple of years now. I even wrote a special investment report on it to help investors better understand the technology and, of course, how to profit from it. [Here’s a link if you want to check it out.]( In any event, last week, I stumbled upon a new study that was published in the scientific journal Circulation that makes me even more bullish on how CRISPR can serve as an effective cure for heart disease. And by the way, one in every four deaths in the U.S. is the result of heart disease. It’s actually the number one leading cause of death in the United States. So as you can imagine, any headway we can make in curing heart disease is a very big deal. Now, in that study, researchers were able to demonstrate, for the first time, how CRISPR technology can be used to determine the risk of a genetic variant for heart disease. You see, today, we can get our DNA sequenced in an effort to hone in on genetic mutations, but these sequences come back as variants. In other words, we get a bunch of information, but it’s hard to determine what all the information means. As a result, doctors have to follow their patients for 10, 20, or 30 years to see if those diseases eventually manifest. In the case of Jacob Sanders and the millions of other people in the world who also have these genetic mutations, even five years can be too long. Now imagine, with the help of CRISPR technology, these folks could not only identify these genetic mutations right away but actually “edit” them out, thereby eliminating the threat of heart disease altogether. This is huge! Digital Doctors Are Disrupting the Health Care Industry! The digital health market is expected to grow by nearly $400 billion over the next five years... And one disruptive tech company already has a 75% market share! [Click here]( to find out how investing in them today could make you 900% gains or more! There are millions of people all across the globe who suffer from heart disease, and today, we’re sitting upon the precipice of a new technology that can not only identify genetic mutations that result in heart disease but effectively treat these mutations before they kill us. This isn’t science fiction, folks. This is very real and very profitable for the companies that have taken the lead on CRISPR technology. Members of my Green Chip Stocks investment community have certainly benefited by getting in early on some of these companies, and many continue to benefit as new treatments are being discovered. Four of these companies are highlighted in a white paper I wrote called “The End of Disease.” You can [get access to this white paper here.]( And like I said earlier, you can also [check out a recent investment report I wrote on CRISPR](, which explains in further detail how CRISPR works and how it could ultimately end every major disease that plagues the world today. From heart disease and cancer to Alzheimer’s and diabetes, CRISPR is next-generation medicine at its finest. To put this in perspective, investing in CRISPR companies today would be like investing in the folks who invented medical imaging in 1895 or organ transplant technology in 1954 or antiviral drugs in the 1960s. Yeah, it’s that big. And quite frankly, only a fool wouldn’t get some exposure to the CRISPR space today, while it’s still in its infancy. There’s just too much money to be made in what is, quite frankly, the biggest medical breakthrough of the 21st century. But don’t just take my word for it. [Click here and see for yourself why what I’m saying is not hyperbole](, but a very real medical breakthrough that’s going to help save a lot of lives while making investors like you a boatload of cash. To a new way of life and a new generation of wealth... [Jeff Siegel Signature] Jeff Siegel [[follow basic]@JeffSiegel on Twitter]( Jeff is the founder and managing editor of Green Chip Stocks, a private investment community that capitalizes on opportunities in alternative energy, organic food markets, legal cannabis, and socially responsible investing. He has been a featured guest on Fox, CNBC, and Bloomberg Asia, and is the author of the best-selling book, Investing in Renewable Energy: Making Money on Green Chip Stocks. For more on Jeff, go to his editor's [page](. Enjoy reading this article? [Click here]( to like it and receive similar articles to read! Browse Our Archives [A Shattering Clash of Hard Plastic]( [Oil Prices Spike 13% in Four Days]( [Investing in High Times: The Most Trusted Brand in Cannabis]( [William Hart's Legacy Is Worth Trillions for Your Portfolio]( [Oil Is Heading Higher]( Related Articles [From Tesla to CRISPR: How Investors Profit from Progress]( --------------------------------------------------------------- This email was sent to {EMAIL}. It is not our intention to send email to anyone who doesn't want it. If you're not sure why you've received this e-letter, or no longer wish to receive it, you may [unsubscribe here](, and view our privacy policy and information on how to manage your subscription. To ensure that you receive future issues of Energy and Capital, please add newsletter@energyandcapital.com to your address book or whitelist within your spam settings. For customer service questions or issues, please contact us for assistance. [Energy and Capital](, Copyright © 2018, [Angel Publishing LLC](. All rights reserved. 111 Market Place #720 Baltimore, MD 21202. The content of this site may not be redistributed without the express written consent of Angel Publishing. Individual editorials, articles and essays appearing on this site may be republished, but only with full attribution of both the author and Energy and Capital as well as a link to www.energyandcapital.com. Your privacy is important to us -- we will never rent or sell your e-mail or personal information. Please read our [Privacy Policy](. No statement or expression of opinion, or any other matter herein, directly or indirectly, is an offer or the solicitation of an offer to buy or sell the securities or financial instruments mentioned. While we believe the sources of information to be reliable, we in no way represent or guarantee the accuracy of the statements made herein. [Energy and Capital]( does not provide individual investment counseling, act as an investment advisor, or individually advocate the purchase or sale of any security or investment. The publisher, editors and consultants of Angel Publishing may actively trade in the investments discussed in this publication. They may have substantial positions in the securities recommended and may increase or decrease such positions without notice. Neither the publisher nor the editors are registered investment advisors. Subscribers should not view this publication as offering personalized legal or investment counseling. Investments recommended in this publication should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company in question.